Santiago Perez-Lloret

Получаване на мой собствен потребителски профил

Позовавания

	Всички	От 2020
Позовавания	8117	4142
h-индекс	46	33
i10-индекс	109	80

860

430

215

645

20052006200720082009201020112012201320142015201620172018201920202021202220232024202525 21 39 37 48 76 132 201 329 360 421 478 524 534 601 684 809 825 831 852 137

Публичен достъп

Преглед на всички

26 статии

1 статия

налични

неналични

Въз основа на изисквания при финансирането

Съавтори

Olivier RASCOLUT3 Professor, CHU Purpan, Tonic (INSERM-UT3), CIC 1436 (INSERM-CHU-UT3), TMBI (Univ. Toulouse)Потвърден имейл адрес: univ-tlse3.fr
Marcelo MerelloProfessor of Neurology. UCA. Director Neuroscience Department FLENIПотвърден имейл адрес: fleni.org.ar
Daniel P. CardinaliConicet, Pontificia Universidad Católica ArgentinaПотвърден имейл адрес: uca.edu.ar
Jean-Louis MontastrucProfessor of Clinical Pharmacology Faculty of Medicine-University Hospital Toulouse FranceПотвърден имейл адрес: univ-tlse3.fr
laurence NEGRE-PAGESПотвърден имейл адрес: chu-montpellier.fr
Malco RossiFLENI - CONICETПотвърден имейл адрес: fleni.org.ar
Wassilios MeissnerПотвърден имейл адрес: chu-bordeaux.fr
Francisco CapaniInvestigador Asociado Universidad Autonoma de Chile and CAECHIS-UAI-CONICET, Buenos AiresПотвърден имейл адрес: uautonoma.cl
Otero-Losada MatildePh D in Neuropharmacology. Res Sci National Research Council CONICET. Buenos Aires. ArgentinaПотвърден имейл адрес: fmed.uba.ar
Anne PAVY LE TRAONHospital practitioner of neurology, CHU Purpan, Equipe 8 UMR1048 (Inserm-UT3), TMBI (Univ. Toulouse)Потвърден имейл адрес: chu-toulouse.fr
Donald MattisonUniversity of South CarolinaПотвърден имейл адрес: risksciences.com
Susan FoxAssociate Professor University of TorontoПотвърден имейл адрес: uhnresearch.ca
Arnaud DelvalUniversité LilleПотвърден имейл адрес: chru-lille.fr
Regina KatzenschlagerKlinik DonaustadtПотвърден имейл адрес: chello.at
Daniel Eduardo VigoPontificia Universidad Católica Argentina - CONICET - KU LeuvenПотвърден имейл адрес: conicet.gov.ar
Daniel Ciampi de Andrade, MD, PhD,...Center for Neuroplasticity and Pain, Fac. of Medicine, Aalborg University, Danmark.Потвърден имейл адрес: hst.aau.dk
Patricio Millar VernettiFLENIПотвърден имейл адрес: fleni.org.ar
Werner PoeweProfessor NeurologieПотвърден имейл адрес: i-med.ac.at
christine Brefel-courbonMCU PH, Neuropharmacologie, CHU Toulouse; TONIC (INSERM UT3); TMBI Univ ToulouseПотвърден имейл адрес: univ-tlse3.fr
veit myliusUniversity of MarburgПотвърден имейл адрес: med.uni-marburg.de

Следене

Santiago Perez-Lloret

Pontificia Universidad Católica Argentina, Consejo de Investigaciones Científicas y Técnicas

Потвърден имейл адрес: uca.edu.ar

Neurodegenerative diseases Parkinson's Disease pharmacology epidemiology public health


Заглавие Сортиране по цитати Сортиране по година Сортиране по заглавие	Позовавания Позовавания	Година
The Movement Disorder Society Evidence‐Based Medicine Review Update: Treatments for the non‐motor symptoms of Parkinson's disease K Seppi, D Weintraub, M Coelho, S Perez‐Lloret, SH Fox, ... Movement disorders 26 (S3), S42-S80, 2011	1147	2011
Update on treatments for nonmotor symptoms of Parkinson's disease—an evidence‐based medicine review K Seppi, K Ray Chaudhuri, M Coelho, SH Fox, R Katzenschlager, ... Movement Disorders 34 (2), 180-198, 2019	969*	2019
Prevalence, determinants, and effect on quality of life of freezing of gait in Parkinson disease S Perez-Lloret, L Negre-Pages, P Damier, A Delval, P Derkinderen, ... JAMA neurology 71 (7), 884-890, 2014	338	2014
Sleep disordered breathing and daytime sleepiness are associated with poor academic performance in teenagers. A study using the Pediatric Daytime Sleepiness Scale (PDSS) D Perez-Chada, S Perez-Lloret, AJ Videla, D Cardinali, MA Bergna, ... Sleep 30 (12), 1698-1703, 2007	261	2007
Deficits in cholinergic neurotransmission and their clinical correlates in Parkinson’s disease S Perez-Lloret, FJ Barrantes NPJ Parkinson's disease 2 (1), 1-12, 2016	199	2016
Drug‐induced parkinsonism: a review of 17 years' experience in a regional pharmacovigilance center in France E Bondon‐Guitton, S Perez‐Lloret, H Bagheri, C Brefel, O Rascol, ... Movement disorders 26 (12), 2226-2231, 2011	183	2011
Autosomal dominant cerebellar ataxias: a systematic review of clinical features M Rossi, S Perez‐Lloret, L Doldan, D Cerquetti, J Balej, P Millar Vernetti, ... European Journal of Neurology 21 (4), 607-615, 2014	160	2014
New treatments for levodopa‐induced motor complications O Rascol, S Perez‐Lloret, JJ Ferreira Movement Disorders 30 (11), 1451-1460, 2015	149	2015
Decision‐making in Parkinson’s disease patients with and without pathological gambling M Rossi, ER Gerschcovich, D De Achaval, S Perez‐Lloret, D Cerquetti, ... European Journal of Neurology 17 (1), 97-102, 2010	148	2010
Dopamine receptor agonists for the treatment of early or advanced Parkinson’s disease S Perez-Lloret, O Rascol CNS drugs 24 (11), 941-968, 2010	143	2010
Sleep disruption in medicine students and its relationship with impaired academic performance: A systematic review and meta-analysis HA Seoane, L Moschetto, F Orliacq, J Orliacq, E Serrano, MI Cazenave, ... Sleep medicine reviews 53, 101333, 2020	134	2020
Sensory abnormalities and pain in Parkinson disease and its modulation by treatment of motor symptoms RG Cury, R Galhardoni, ET Fonoff, S Pérez Lloret, ... European journal of pain 20 (2), 151-165, 2016	129	2016
A multi-step pathway connecting short sleep duration to daytime somnolence, reduced attention, and poor academic performance: an exploratory cross-sectional study in teenagers S Perez-Lloret, AJ Videla, A Richaudeau, D Vigo, M Rossi, DP Cardinali, ... Journal of Clinical Sleep Medicine 9 (5), 469-473, 2013	127	2013
Addenbrooke’s Cognitive Examination validation in Parkinson’s disease MA Reyes, SP Lloret, ER Gerscovich, ME Martin, R Leiguarda, M Merello European Journal of Neurology 16 (1), 142-147, 2009	127	2009
Prevalence and pharmacological factors associated with impulse-control disorder symptoms in patients with Parkinson disease S Perez-Lloret, MV Rey, N Fabre, F Ory, U Spampinato, C Brefel-Courbon, ... Clinical neuropharmacology 35 (6), 261-265, 2012	115	2012
Associations between anticholinergic burden and adverse health outcomes in Parkinson disease JAG Crispo, AW Willis, DP Thibault, Y Fortin, HD Hays, DS McNair, ... PLoS One 11 (3), e0150621, 2016	110	2016
Oro‐buccal symptoms (dysphagia, dysarthria, and sialorrhea) in patients with Parkinson’s disease: preliminary analysis from the French COPARK cohort S Perez‐Lloret, L Nègre‐Pagès, A Ojero‐Senard, P Damier, A Destée, ... European journal of neurology 19 (1), 28-37, 2012	108	2012
Validation of a new scale for the evaluation of sialorrhea in patients with Parkinson's disease S Perez Lloret, G Pirán Arce, M Rossi, ML Caivano Nemet, P Salsamendi, ... Movement disorders 22 (1), 107-111, 2007	106	2007
A multifactorial approach employing melatonin to accelerate resynchronization of sleep–wake cycle after a 12 time‐zone westerly transmeridian flight in elite soccer athletes DP Cardinali, GP Bortman, G Liotta, SP Lloret, LE Albornoz, RA Cutrera, ... Journal of pineal research 32 (1), 41-46, 2002	94	2002
Efficacy and safety of amantadine for the treatment of l-DOPA-induced dyskinesia S Perez-Lloret, O Rascol Journal of Neural Transmission 125, 1237-1250, 2018	93	2018

Системата не може да изпълни операцията сега. Опитайте отново по-късно.

Статии 1–20

Позовавания годишно

Дублирани описания

Обединени библиографски описания

Добавяне на съавториСъавтори

Следене

Позовавания

Съавтори